Article Information
History
- August 13, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Valérie Gounant, MD, MSc.1,2,*,
- Valentine Marie Ferré, PharmD, MSc.3,*,
- Ghassen Soussi, MD1,2,
- Charlotte Charpentier, PharmD, PhD3,
- Héloïse Flament, PharmD, PhD4,
- Nadhira Fidouh, PharmD3,
- Gilles Collin, Msc.3,
- Céline Namour, MSc.1,2,
- Sandra Assoun, MD, Msc1,2,
- Alexandra Bizot, MD, MSc.1,2,
- Zohra Brouk, PhD1,2,
- Eric Vicaut, MD, PhD5,
- Luis Teixeira, MD, PhD6,
- Diane Descamps, MD, PhD3 and
- Gérard Zalcman, MD, PhD1,2,7,¶
- 1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
- 2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
- 3Université de Paris, Virology Department, INSERM UMR1137 “Infection, Antimicrobials, Modelling, Evolution”, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
- 4Université de Paris, Hematology and Immunology Department, INSERM-U1149, Research Center on Inflammation (CRI) Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
- 5Université de Paris, Biostatistics and Clinical Research Department, Lariboisière Hospital (AP-HP.Nord), 2 rue Amboise Paré, 75018 Paris, France
- 6Université de Paris, North-Paris Cancer University Institute, Breast Diseases Centre, INSERM U976, HIPI, “Pathophysiology of Breast Cancer Team”, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 1 avenue Claude Vellefaux, 75010 Paris, France
- 7INSERM U830 “Cancer, Heterogeneity Plasticity”, Curie Institute Research Centre, 26 rue d’Ulm, 75231 Paris cedex 05, France
- ↵¶To whom correspondence must be addressed: Prof. G. Zalcman
Service d’ Oncologie Thoracique Hôpital Bichat-Claude Bernard 46 rue Henri Huchard FR-75018 Paris gerard.zalcman{at}aphp.fr
↵* both authors equally contributed
Posted August 13, 2021.
Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses
